Nano Diagnostic Chains
Market Cap
₹253 ₹253 Cr.
P/E
14.55
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.34
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
-
Institutions
Institutions
-
Market cap
Market cap
253 Cr
No. of Shareholders
No. of Shareholders
-
OPM (%)
OPM (%)
-
PE
PE
14.55
Prom Holding
Prom Holding
-
ROCE (%)
ROCE (%)
37.64
ROE (%)
ROE (%)
32.69
Sales
Sales
62.29 Cr
  • Pramodini Medicare
  • Invicta Diagnostic
  • Krsnaa Diagnostics
Last updated on 7 Oct 2026
  • Pramodini Medicare runs diagnostic centres under its Pramodini Imaging & Diagnostics brand. It offers radiology, laboratory and nuclear-medicine services.
  • It serves hospitals, standalone walk-ins and public-sector partners, mostly in Andhra Pradesh and Karnataka. It has moved away from mainly government partnerships.
  • Profit comes almost entirely from radiology at ~97% of revenue, with laboratory and nuclear medicine tiny. Asset growth has raised employee and depreciation costs.
  • Per management, its edge is equipment depth and one-stop radiology, laboratory and nuclear-medicine services across its network.
  • It is adding ₹45.15Cr of equipment across its centres. It has added a cardiac associate and a scanner site in Uttar Pradesh.
  • Revenue grew sharply in FY26 but margins slipped. EBITDA margin fell to 49.61% from 54.83% as employee and depreciation costs rose.
  • Working capital absorbs cash. Customer dues stay unpaid for months and large supplier advances tie up funds.
  • It is in a heavy build phase. Near-term profit depends on new capacity filling up.
  • Statutory filings have been late and past records are incomplete. A charge filing and a recent associate disclosure also show gaps.
  • IPO price and proceeds Offer Aug 2026 elapsed; listing confirmed Oct 2026
    Final price and fresh proceeds settle funding for the ₹45.15Cr equipment plan and post-offer holding.
  • Kodagu cardiac operating concession No timeline
    Execution settles terms, funding and start date for the long-term cardiac operating concession.
  • CT scanner in Maharajganj, Uttar Pradesh No COD stated
    Purchase cost and commissioning settle the first footprint outside Andhra Pradesh and Karnataka.
  • Diagnostic equipment in Hubli No COD stated
    The ₹16.35Cr installation settles capacity uplift and spend against the equipment programme.
  • Diagnostic equipment in Bangalore No COD stated
    The ₹11.25Cr installation settles capacity uplift and spend against the equipment programme.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
110
52W Range
High
137
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

3 Neutral

Neutral for this company

1 No

Negative for this company

5 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Customer Segment

Peer Comparison

FAQs on Pramodini Medicare Ltd. Business

Pramodini Medicare Limited, incorporated in 2000, is a diagnostic service provider offering technology-enabled healthcare services. The company operates in the diagnostics segment across radiology, clinical laboratory, nuclear medicine, and teleradiology services through multiple partnership models.

Pramodini Medicare major competitors are Invicta Diagnostic, Krsnaa Diagnostics, Star Imaging & Path.
Market Cap of Pramodini Medicare is ₹254 Crs.
While the median market cap of its peers are ₹130 Crs.

Pramodini Medicare seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material